GlassScriptPhysician profile
Andrew Bryant
NPI 1194018093
$2,217.30
in general payments reported to CMS, 2019-2025
20 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2022: $24.63 · 2023: $737 · 2024: $871 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $319.62 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $296.56 | 2023-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $289.59 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $256.08 | 2023-2024 | |
| Exact Sciences Corporation | $225.20 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $137.66 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.79 | 2023-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $99.69 | 2023 | Verquvo, Belsomra, Steglatro |
| Dexcom, INC. | $79.04 | 2024-2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $75.40 | 2023-2024 | Qutenza |
| Janssen Biotech, INC. | $67.15 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $60.09 | 2023-2025 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $42.88 | 2023-2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $33.62 | 2024 | |
| Glaxosmithkline, LLC. | $30.89 | 2024-2025 | Trelegy Ellipta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.56 | 2024 | Spevigo |
| Medtronic, INC. | $26.93 | 2024 | Closurefast |
| Sun Pharmaceutical Industries INC. | $20.21 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.30 | 2024 | Camzyos |
| Gilead Sciences, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.